Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

Hormonal side effects in women: typical versus atypical antipsychotic treatment.

Dickson RA, Seeman MV, Corenblum B.

J Clin Psychiatry. 2000;61 Suppl 3:10-5. Review.

2.

[Atypical antipsychotics and sexual dysfunction: five case-reports associated with risperidone].

Haefliger T, Bonsack C.

Encephale. 2006 Jan-Feb;32(1 Pt 1):97-105. French.

PMID:
16633296
3.

Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.

Kim KS, Pae CU, Chae JH, Bahk WM, Jun TY, Kim DJ, Dickson RA.

J Clin Psychiatry. 2002 May;63(5):408-13.

PMID:
12019665
4.

Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?

O'Keane V, Meaney AM.

J Clin Psychopharmacol. 2005 Feb;25(1):26-31.

PMID:
15643097
5.

Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients.

Ghadirian AM, Chouinard G, Annable L.

J Nerv Ment Dis. 1982 Aug;170(8):463-7.

PMID:
6124580
6.

Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone.

Kinon BJ, Gilmore JA, Liu H, Halbreich UM.

Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:55-68.

PMID:
12650681
7.

[Impact of neuroleptic-induced hyperprolactinemia on sexual dysfunction in male schizophrenic patients].

Konarzewska B, Szulc A, Popławska R, Galińska B, Juchnowicz D.

Psychiatr Pol. 2008 Jan-Feb;42(1):87-95. Review. Polish.

PMID:
18567406
8.

Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.

O'Keane V.

J Psychopharmacol. 2008 Mar;22(2 Suppl):70-5. doi: 10.1177/0269881107088439. Review.

PMID:
18477623
9.

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Haddad PM, Wieck A.

Drugs. 2004;64(20):2291-314. Review.

PMID:
15456328
10.

The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis.

Smith S, Wheeler MJ, Murray R, O'Keane V.

J Clin Psychopharmacol. 2002 Apr;22(2):109-14.

PMID:
11910254
11.

Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects.

Halbreich U, Kinon BJ, Gilmore JA, Kahn LS.

Psychoneuroendocrinology. 2003 Jan;28 Suppl 1:53-67. Review.

PMID:
12504072
12.

Hyperprolactinemia in a patient with a pituitary adenoma receiving antipsychotic drug therapy.

Carroll RW, Christodoulou P, Baynes KC, Kahn DA.

J Psychiatr Pract. 2012 Mar;18(2):126-9. doi: 10.1097/01.pra.0000413279.95843.b5.

PMID:
22418404
13.

Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment.

Montgomery J, Winterbottom E, Jessani M, Kohegyi E, Fulmer J, Seamonds B, Josiassen RC.

J Clin Psychiatry. 2004 Nov;65(11):1491-8.

PMID:
15554761
14.

Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia.

Nakajima M, Terao T, Iwata N, Nakamura J.

Pharmacopsychiatry. 2005 Jan;38(1):17-9.

PMID:
15706461
15.

Antipsychotic-induced hyperprolactinemia and sexual dysfunction.

Compton MT, Miller AH.

Psychopharmacol Bull. 2002 Winter;36(1):143-64. Review.

PMID:
12397853
16.

[Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].

Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C.

Encephale. 2014 Feb;40(1):86-94. doi: 10.1016/j.encep.2012.03.002. Epub 2013 Aug 5. Review. French.

PMID:
23928066
17.

Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology.

Windgassen K, Wesselmann U, Schulze Mönking H.

Neuropsychobiology. 1996;33(3):142-6.

PMID:
8776743
18.

[The relationship between antipsychotic-induced hyperprolactinemia and menstrual disorders in women with schizophrenia; a systematic review].

Ouwehand AJ, Mollema-Schelwald BM, Knegtering H.

Tijdschr Psychiatr. 2012;54(10):861-8. Review. Dutch.

19.

Prolactin awareness: an essential consideration for physical health in schizophrenia.

Montejo AL.

Eur Neuropsychopharmacol. 2008 May;18 Suppl 2:S108-14. doi: 10.1016/j.euroneuro.2008.02.004. Review.

PMID:
18346598

Supplemental Content

Support Center